Characteristics of a CCL21 Gene-Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non-Small Cell Lung Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Michael S,Oh

第一单位： Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

作者： Michael S,Oh ^[1] ; Camelia,Dumitras ^[1] ; Ramin,Salehi-Rad ^[2] ; Linh M,Tran ^[3] ; Kostyantyn,Krysan ^[3] ; Raymond J,Lim ^[1] ; Zhe,Jing ^[1] ; Shahed,Tappuni ^[1] ; Aaron,Lisberg ^[3] ; Edward B,Garon ^[3] ; Steven M,Dubinett ^[2] ; Bin,Liu ^[3]

作者单位： Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California. ^[1] Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.;Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California.;Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California. ^[2] Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.;Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California. ^[3]

主题词人类(Humans);树突细胞(Dendritic Cells);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);趋化因子CCL21(Chemokine CCL21);癌症疫苗(Cancer Vaccines);肺肿瘤(Lung Neoplasms)

DOI 10.1158/1535-7163.MCT-24-0435

PMID 39559833

发布时间 2025-02-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交